Mr. Nir Nirmodi is Replacing Ms. Sarit Firon,
who will Continue Serving as a Member of the Board
REHOVOT, Israel, March 6,
2025 /PRNewswire/ -- Evogene Ltd. (Nasdaq:
EVGN) (TASE: EVGN), a leading computational biology company aiming
to revolutionize life-science-based product discovery and
development, today announced the appointment of Mr. Nir Nimrodi as the new Chairperson of the Board,
succeeding Ms. Sarit Firon, who has held the position since
August 2021. Ms. Firon will continue
to serve as a member of the Board.
As Evogene progresses toward key milestones across its
subsidiaries and programs, Mr. Nimrodi's extensive experience in
scaling life sciences businesses and driving growth makes him
well-suited to guide the company's next phase. His leadership will
strengthen ongoing efforts and build upon the solid foundation
established under Ms. Firon's tenure. Mr. Nimrodi, a member of the
Evogene Board since September 2022,
brings over two decades of extensive international experience
across both start-ups and large global organizations within the
life sciences, pharmaceutical, and biotechnology sectors.
"On behalf of Evogene, I am pleased to welcome Nir Nimrodi as the new Chairperson of the
Board," said Ofer Haviv,
President and CEO of Evogene. "Mr. Nimrodi has been actively
engaged in Evogene's activities since 2020, initially serving as a
special advisor to the Board, and subsequently as a member. With
his appointment as Chairperson, I look forward to collaborating
closely with him as Evogene continues on its journey. I would also
like to express my gratitude to Sarit Firon for her invaluable
contributions as Chairperson, and I am pleased that she will
continue to support Evogene in her role as a Board member."
"I am excited about the opportunities ahead for Evogene," said
Nir Nimrodi. "Several of the
company's assets have the potential to create significant value for
Evogene and its shareholders, and I am committed to focusing on
strategies that will unlock this value starting this year.
Additionally, Evogene has been leveraging advanced computational
capabilities to drive product innovation for the past two decades.
With the growing potential of AI, a field in which Evogene is
already a natural leader, we intend to further harness our
expertise to advance the drug discovery process and enhance the
value we bring to this space."
In addition, Evogene's President and CEO, Mr. Ofer Haviv, will join as member of the Board,
and will remain in office until the earlier of the first annual or
special general meeting of shareholders following his
appointment.
About Evogene Ltd.
Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN) is a computational
biology company leveraging big data and artificial intelligence,
aiming to revolutionize the development of life-science based
products by utilizing cutting-edge technologies to increase the
probability of success while reducing development time and
cost.
Evogene established three unique tech-engines - MicroBoost
AI, ChemPass AI and GeneRator AI. Each tech-engine
is focused on the discovery and development of products based on
one of the following core components: microbes (MicroBoost
AI), small molecules (ChemPass AI), and genetic elements
(GeneRator AI).
Evogene uses its tech-engines to develop products through
strategic partnerships and collaborations, and its four
subsidiaries including:
- Casterra Ag Ltd. (www.casterra.co)– developing and marketing
superior castor seed varieties producing high yield and high-grade
oil content, on an industrial scale for the biofuel and other
industries powered by GeneRator AI.
- Lavie Bio Ltd. (www.lavie-bio.com) - developing and
commercially advancing, microbiome based ag-biologicals powered by
MicroBoost AI;
- AgPlenus Ltd. (www.agplenus.com) -developing next generation ag
chemicals for effective and sustainable crop protection powered by
ChemPass AI; and
- Biomica Ltd. (www.biomicamed.com) developing and advancing
novel microbiome-based therapeutics to treat human disorders
powered by MicroBoost AI;
For more information, please visit:
www.evogene.com.
Forward-Looking Statements
This press release contains "forward-looking statements"
relating to future events. These statements may be identified by
words such as "may", "could", "expects", "hopes" "intends",
"anticipates", "plans", "believes", "scheduled", "estimates",
"demonstrates" or words of similar meaning. For example, Evogene
and its subsidiaries are using forward-looking statements in this
press release when it discusses the belief that the company's
assets have the potential to create significant value for the
Company and its shareholders and the success of advancing the drug
discovery process. Such statements are based on current
expectations, estimates, projections and assumptions, describe
opinions about future events, involve certain risks and
uncertainties which are difficult to predict and are not guarantees
of future performance. Therefore, actual future results,
performance or achievements of Evogene and its subsidiaries may
differ materially from what is expressed or implied by such
forward-looking statements due to a variety of factors, many of
which are beyond the control of Evogene and its subsidiaries,
including, without limitation, the current war between
Israel and Hamas and any worsening
of the situation in Israel such as
further mobilizations or escalation in the northern border of
Israel and those
risk factors contained in Evogene's reports filed with the
applicable securities authority. In addition, Evogene and its
subsidiaries rely, and expect to continue to rely, on third parties
to conduct certain activities, such as their field-trials and
pre-clinical studies, and if these third parties do not
successfully carry out their contractual duties, comply with
regulatory requirements or meet expected deadlines, Evogene and its
subsidiaries may experience significant delays in the conduct of
their activities. Evogene and its subsidiaries disclaim any
obligation or commitment to update these forward-looking statements
to reflect future events or developments or changes in
expectations, estimates, projections and assumptions.
Contact:
ir@evogene.com
Tel: +972-8-9311901
Logo -
https://mma.prnewswire.com/media/1947468/Evogene_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/evogene-announces-the-appointment-of-nir-nimrodi-as-the-new-chairperson-of-the-board-effective-march-5-2025-302394573.html
SOURCE Evogene
